Ketoprofen is under clinical development by Achelios Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ketoprofen’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ketoprofen Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ketoprofen (ELSM-11, Topofen) is under development for the treatment of a migraine, temporomandibular joint disorders, osteoarthritis and sprains and strains. The drug candidate is applied topically as formulated in the gel and liquid spray forms. The drug candidate acts by targeting prostaglandin G/H synthase (cyclooxygenase or COX).
Achelios Therapeutics overview
Achelios Therapeutics (Achelios) is a provider of pharmaceutical products and services.It develops therapeutics for the treatment of pain and inflammation by topically delivered medications. The company’s products portfolio includes Topofen, a product for the indication of acute migraine, temporomandibular joint disorders, prophylaxis migraine, osteoarthritis, and sprains and strains; and achetogel, a gel-based formulation that enables transdermal penetration of active ingredients to the target tissue. Achelios’ develops novel formulations using its proprietary topogel and achetogel delivery technology. It owns and operates a medication research laboratories located in San Diego, California, the US. Achelios is headquartered in Chapel Hill, North Carolina, the US.
Quick View Ketoprofen LOA Data
|Highest Development Stage|